Skip to main content
SpringerLink
Log in

Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336–4342.

    Article  CAS  PubMed  Google Scholar 

  2. Witzig TE, White CA, Wiseman GA, Gordon IE, Raubitschek N, Janakiraman CEA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793–3803.

    Article  CAS  PubMed  Google Scholar 

  3. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN et al. White treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 2: 3262–3269.

    Article  Google Scholar 

  4. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–1266.

    CAS  PubMed  Google Scholar 

  5. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461–467.

    Article  CAS  PubMed  Google Scholar 

  6. Vose JM, Biermann PJ, Loberiza FR, Bociek RG, Matso D, Armitage JO . Phase I trial of 90Y-ibritumnumyb tiutexan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007; 48: No4, pp 683–690.

    Google Scholar 

  7. Molina A, Krishnan A, Fung H, Flinn IW, Inwards D, Winter J et al. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiutexan. Curr Stem Cell Res Ther 2008; 2: 239–248.

    Article  Google Scholar 

  8. Jacobs SA, Vidnovic N, Joyce J, McCook B, Torok F, Avril N . Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005; 11: 7146s–7150s.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Georg August University, Göttingen, Germany

    K Hohloch, G G Wulf & L H Truemper

  2. Department of Hematology/Oncology, Istituto Seragnoli, University of Bologna, Bologna, Italy

    P L Zinzani

  3. Department of Hematology and Stem Cell Transplantation, Medical University of Graz, Graz, Austria

    W Linkesch

  4. Haematology/Oncology, University of Krakow, Krakow, Poland

    W Jurczak

  5. Haematology/Oncology, Central Hospital Warszawa, Warszawa, Poland

    A Deptala

  6. Alcedis GmbH, Giessen, Germany

    M Lorsbach & C Windemuth-Kiesselbach

Authors
  1. K Hohloch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P L Zinzani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Linkesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Jurczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Deptala
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Lorsbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Windemuth-Kiesselbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G G Wulf
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L H Truemper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Hohloch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hohloch, K., Zinzani, P., Linkesch, W. et al. Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network. Bone Marrow Transplant 46, 901–903 (2011). https://doi.org/10.1038/bmt.2010.202

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.202

  • Springer Nature Limited

Search

Navigation